Defending neurodiversity in the face of Trump’s Tylenol-autism claims

It’s been just over a week since the Trump administration very publicly claimed that Tylenol usage is linked to an increased rate of autism.

Based on dubious evidence, the White House asserted that acetaminophen – the active ingredient in Tylenol – is what’s behind the “current autism epidemic.”

For all of the bluster and upheaval that arose from the communications coming out of 1600 Pennsylvania Avenue, there are real lessons to be learned for health brands and medical marketers on a professional level.

However, on a personal level, there is also plenty that can be learned from those living on the spectrum or caring for those who do.

On this episode, managing editor Jack O’Brien moderates an in-depth, critical conversation about the Tylenol-autism controversy between editor-in-chief Jameson Fleming and Rachel Lowenstein, co-founder and chief creative officer of the Neu Project, a creative consultancy.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.